Please wait a minute...
J Zhejiang Univ (Med Sci)  2021, Vol. 50 Issue (4): 420-428    DOI: 10.3724/zdxbyxb-2021-0246
    
Eye diseases burden in China in the past 30 years
CHEN Binbin(),LOU Lixia(),YE Juan
Ophthalmology Center, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China
Download: HTML( 14 )   PDF(2907KB)
Export: BibTeX | EndNote (RIS)      

Abstract  

Objective: To investigate the national burden of eye diseases in China from 1990 to 2019. Methods: The national burden of eye diseases in China, including case numbers, prevalence rate, age-standardized prevalence rate (ASR), disability-adjusted life year (DALY), DALY rate and age-standardized DALY rate (ASD) were calculated and stratified by sex and age. The trends of eye diseases burden from 1990 to 2019 and the correlation between eye diseases burden and human development index (HDI) were analyzed. Results: In 2019, the total case number of eye diseases in China was 0.21 billion, the ASR was 9511/105, the total number of DALY was 4.72 million, and the ASD was 247.4/105. Near vision loss caused the greatest burden, followed by refraction disorders and cataract, with ASD being 73.8/105, 70.3/105 and 59.2/105, respectively. Men had lower risks of eye diseases than women. People aged 50– <70?years old and ≥70?years old had the greatest burden of eye diseases. Compared with the year 1990, the total case number increased by 134.6% and DALY by 113.0% in 2019. The ASD of all decreased by 7.5%, and was negatively correlated with national HDI. Conclusions: Near vision loss, refraction disorders and cataract are of heavy disease burden in China. Although the ASD of eye diseases is decreased with the development of the national socioeconomic status, the eye diseases burden in China still increased with population growth and aging.



Key wordsEye disease      Prevalence      Disability-adjusted life year      Burden of disease      Human development index     
Received: 29 January 2021      Published: 01 November 2021
CLC:  R77  
  R195.4  
Corresponding Authors: LOU Lixia     E-mail: 2201015@zju.edu.cn;loulixia110@zju.edu.cn
Cite this article:

CHEN Binbin,LOU Lixia,YE Juan. Eye diseases burden in China in the past 30 years. J Zhejiang Univ (Med Sci), 2021, 50(4): 420-428.

URL:

http://www.zjujournals.com/med/10.3724/zdxbyxb-2021-0246     OR     http://www.zjujournals.com/med/Y2021/V50/I4/420


中国眼病疾病负担现状及三十年变化趋势

目的:分析1990—2019年中国眼病的疾病负担状况和变化趋势。方法:利用2019年全球疾病负担研究结果,分析1990—2019年中国眼病患病人数、患病率、年龄标化患病率、伤残调整生命年(DALY)、DALY率、年龄标化DALY率及变化趋势,以及年龄标化DALY率与国家社会经济发展水平之间的相关性。结果:2019年中国人群眼病患病人数为2.1亿,年龄标化患病率为9511/10万;总DALY为472万,年龄标化DALY率为247.4/10万。疾病负担较重的眼病依次为近视力丧失、屈光性眼病和白内障,年龄标化DALY率分别为73.8/10万、70.3/10万和59.2/10万。男性患各类眼病的风险均低于女性。疾病负担较重的年龄段为50~<70岁和≥70岁。相比于1990年,2019年中国人群眼病患病数增加了134.6%,总DALY增加了113.0%。然而,总体年龄标化DALY率下降了7.5%,与国家社会经济发展水平呈明显负相关(P<0.01)。结论:在中国,近视力丧失、屈光性眼病和白内障是疾病负担较重的眼病。尽管近年来随着国家的发展,眼病年龄标化DALY率有所下降,但人口增长和老龄化导致了眼病造成的疾病负担显著上升。


关键词: 眼病,  患病率,  伤残调整生命年,  疾病负担,  人类发展指数 

疾病名称

年份

患病数

患病率(×10–5

年龄标化患病率(×10–5

男?性

女?性

合?计

男?性

女?性

平?均

男?性

女?性

平?均

青光眼

1990年

310? 404

272?622

583?026

51

48

49

107

76

89

2019年

660?125

678?085

1?338?210

91

97

94

77

67

71

变化率(%)

112.7

148.7

129.5

79.0

104.5

91.0

–28.0

–11.9

–19.6

白内障

1990年

2? 218 ?032

3?389?569

5?607?601

364

591

474

753

947

867

2019年

6 ?982? 584

11?159?985

18?142?569

963

1600

1276

834

1117

992

变化率(%)

214.8

229.2

223.5

165.0

170.7

169.2

10.8

18.0

14.4

老年性黄斑变性

1990年

370? 033

517?406

887?439

61

90

75

109

131

121

2019年

1?124 ?034

1?477?849

2?601?883

155

212

183

121

142

132

变化率(%)

203.8

185.6

193.2

155.7

134.8

144.0

11.0

7.9

8.8

屈光性眼病

1990年

6?873?104

7?942?665

14?815?769

1126

1385

1252

1443

1664

1558

2019年

12?187? 806

15?088?866

27?276?672

1681

2163

1918

1416

1687

1552

变化率(%)

77.3

90.0

84.1

49.3

56.2

53.2

–1.8

1.4

–0.3

近视力丧失

1990年

29?041?571

34?896?773

63?938?344

4759

6085

5402

6946

8075

7538

2019年

68?909?162

83?487?020

152?396?182

9507

11?969

10?714

6856

7890

7393

变化率(%)

137.3

139.2

138.3

99.8

96.7

98.4

–1.3

–2.3

–1.9

其他视力丧失

1990年

1?416?174

1?620?661

3?036?835

232

283

257

332

374

356

2019年

2?886?243

3?800?722

6?686?965

398

545

470

319

383

353

变化率(%)

103.8

134.5

120.2

71.6

92.8

83.2

–3.8

2.5

–0.8

合计

1990年

40?229?318

48?639?697

88?869?015

6154

7715

6910

8807

10?070

9464

2019年

92?749?955

115?692?525

208?442?480

11?853

14?937

13?365

8831

10?149

9511

变化率(%)

130.6

137.9

134.6

92.6

93.6

93.4

0.3

0.8

0.5

Table 1 Prevalence, prevalence rates, and age-standardized prevalence rates of eye diseases in China in the year 1990 and 2019
Figure 1 Prevalence, prevalence rates and age-standardized prevalence rates of eye diseases in China during 1990 and 2019

疾病名称

年份

DALY

DALY率(×10–5

年龄标化DALY率(×10–5

男性

女性

合计

男性

女性

平均

男性

女性

平均

青光眼

1990年

37?549

29?718

67?267

6.2

5.2

5.7

12.8

8.3

10.1

2019年

58?063

54?466

112?528

8.0

7.8

7.9

6.7

5.4

6.0

变化率(%)

54.6

83.3

67.3

30.2

50.7

39.2

–47.3

–34.8

–40.9

白内障

1990年

180?718

268?605

449?323

29.6

46.8

38.0

56.4

72.4

65.8

2019年

420?304

667?683

1?087?987

58.0

95.7

76.5

49.1

66.8

59.2

变化率(%)

132.6

148.6

142.1

95.8

104.4

101.5

–13.0

–7.7

–10.2

老年性黄斑变性

1990年

22?133

32?752

54?885

3.6

5.7

4.6

6.5

8.3

7.5

2019年

59?227

82?839

142?066

8.2

11.9

10.0

6.4

7.9

7.2

变化率(%)

167.6

152.9

158.8

125.3

108.0

115.4

–1.7

–4.3

–3.6

屈光性眼病

1990年

316?967

369?088

686?055

51.9

64.4

58.0

68.1

78.6

73.6

2019年

567?561

701?632

1?269?193

78.3

100.6

89.2

64.5

76.0

70.3

变化率(%)

79.1

90.1

85.0

50.7

56.3

54.0

–0.9

–1.8

–1.4

近视力丧失

1990年

293?584

347?115

640?699

48.1

60.5

54.1

69.6

79.9

74.9

2019年

695?932

831?263

1?527?195

96.0

119.2

107.4

68.9

78.4

73.8

变化率(%)

137.0

139.5

138.4

99.6

96.9

98.4

–0.9

–1.8

–1.4

其他视力丧失

1990年

160?116

156?521

316?637

26.2

27.3

26.8

35.3

35.0

35.4

2019年

271?061

308?180

579?241

37.4

44.2

40.7

30.1

31.3

30.9

变化率(%)

69.3

96.9

82.9

42.5

61.9

52.2

–14.9

–10.4

–12.7

合计

1990年

1?011?067

1?203?800

2?214?867

165.7

209.9

187.1

248.6

282.4

267.4

2019年

2?072?149

2?646?063

4?718?212

285.9

379.3

331.7

225.7

266.0

247.4

变化率(%)

104.9

119.8

113.0

72.5

80.7

77.3

–9.2

–5.8

–7.5

Table 2 DALYs, DALY rates, and age-standardized DALY rates of eye diseases in China in the year 1990 and 2019

疾病名称

年份

DALY

DALY率(×10–5

<5岁

5~<15岁

15~<50岁

50~<70岁

≥70岁

<5岁

5~<15岁

15~<50岁

50~<70岁

≥70岁

青光眼

1990年

225

25?158

41?884

0.03

16.3

109.5

2019年

451

40?897

71?181

0.06

11.1

65.9

变化率(%)

100.4

62.6

69.9

86.1

–32.1

–39.8

白内障

1990年

58?459

153?315

237?550

8.7

99.5

620.9

2019年

67?175

366?080

654?733

9.3

99.2

606.4

变化率(%)

14.9

138.8

175.6

6.6

–0.3

–2.3

老年性黄斑变性

1990年

211

26?691

27?983

0.03

17.3

73.1

2019年

465

65?538

76?062

0.06

17.8

70.5

变化率(%)

120.1

145.5

171.8

104.1

2.5

–3.7

屈光性眼病

1990年

17?531

59?938

199?333

256?966

152?288

15.2

28.9

29.8

166.8

398.1

2019年

12?789

48?467

265?542

582?423

359?973

15.7

33.8

36.8

157.9

333.4

变化率(%)

–27.0

–19.1

33.2

126.7

136.4

3.3

7.1

23.6

–5.3

–16.2

近视力丧失

1990年

81

601

104?887

364?779

170?350

0.07

0.29

15.7

236.8

445.3

2019年

63

448

212?518

884?410

429?756

0.08

0.31

29.5

239.8

398.1

变化率(%)

–22.2

–25.4

102.6

142.5

152.3

10.1

8.0

87.9

1.3

–10.6

其他视力丧失

1990年

6253

15?810

98?615

116?486

79?474

5.4

7.6

14.8

75.6

207.7

2019年

4339

8254

82?063

260?460

224?126

5.3

5.8

11.4

70.6

207.6

变化率(%)

–30.6

–47.8

–16.8

123.6

182.0

–1.7

–24.4

–22.8

–6.6

–0.1

合计

1990年

23?866

76?349

461?729

943?394

709?529

20.7

36.8

69.1

612.4

1854.6

2019年

17?191

57?169

628?213

2?199?807

1?815?831

21.1

39.9

87.2

596.3

1681.9

变化率(%)

–28.0

–25.1

36.1

133.2

155.9

2.0

8.4

26.2

–2.6

–9.3

Table 3 DALYs and DALY rates of eye diseases in population of different ages in China in the year 1990 and 2019
Figure 2 DALYs, DALY rates and age-standardized DALY rates of eye diseases in China during 1990 and 2019
Figure 3 Line regression between age-standardized DALY rates and human development index in China during 1990 and 2019

因变量

调整R2

标准化β系数

P

青光眼

0.717

–0.862

0.000

白内障

0.682

–0.843

0.001

老年性黄斑变性

0.565

–0.778

0.003

近视力丧失

0.972

–0.987

0.003

其他视力丧失

0.663

–0.833

0.001

Table 4 Linear regression results of age-standardized DALY rates of eye diseases and human development index in China during 1990 and 2019
[1]   Global Health Data Exchange. Global burden of disease study 2019 data resources[EB/OL]. [2020-12-28]. http://ghdx.healthdata.org/gbd-2019
[2]   高 华, 陈秀念, 史伟云. 我国盲的患病率及主要致盲性疾病状况分析[J]. 中华眼科杂志, 2019, 55(8): 625-628
GAO Hua, CHEN Xiunian, SHI Weiyun. Analysis of the prevalence of blindness and major blinding diseases in China[J]. Chinese Journal of Ophthalmology, 2019, 55(8): 625-628. (in Chinese)
[3]   World Health Organization. What is VISION 2020? [EB/OL]. [2020-10-15]. https://www.who.int/blindness/partnerships/vision2020/en/
[4]   中华人民共和国国家卫生健康委员会. 国家卫生计生委关于印发“十三五”全国眼健康规划(2016—2020年)的通知[EB/OL]. (2016-11-09)[2020-10-01]. http://www.nhc.gov.cn/wjw/ghjh/201611/9463afb00ac84910bb3c22f8629cf90a.shtml
National Health Commission of the People’s Republic of China. Notice of “The 13th Five-Year plan” of national eye health (2016-2020) published by National Health and Family Planning Commission[EB/OL]. (2016-11-09)[2020-10-01]. http://www.nhc.gov.cn/wjw/ghjh/201611/9463afb00ac84910bb3c22f8629cf90a.shtml. (in Chinese)
[5]   Global Health Data Exchange. GBD results tool[EB/OL]. [2020-12-24]. http://ghdx.healthdata.org/gbd-results-tool
[6]   United Nations Development Programme. Human development report 2020[EB/OL]. [2021-01-12]. http://hdr.undp.org/en/2020-report
[7]   ZHAOJ, XUX, ELLWEINL B, et al.Prevalence of vision impairment in older adults in rural China in 2014 and comparisons with the 2006 China nine-province survey[J]Am J Ophthalmol, 2018, 81-93.
doi: 10.1016/j.ajo.2017.10.016
[8]   HOLDENB A, FRICKET R, HOS M, et al.Global vision impairment due to uncorrected presbyopia[J]Arch Ophthalmol, 2008, 126( 12): 1731.
doi: 10.1001/archopht.126.12.1731
[9]   中华人民共和国国家统计局. 中华人民共和国2019年国民经济和社会发展统计公报[EB/OL]. (2020-02-28)[2020-10-05]. http://www.stats.gov.cn/tjsj/zxfb/202002/t20200228_1728913.html
National Bureau of Statistics of the People’s Republic of China. National economic and social development report of the People’s Republic of China in 2019[EB/OL]. (2020-02-28)[2020-10-05]. http://www.stats.gov.cn/tjsj/zxfb/202002/t20200228_1728913.html. (in Chinese)
[10]   ZHAOJ, XUX, ELLWEINL B, et al.Causes of visual impairment and blindness in the 2006 and 2014 nine-province surveys in rural China[J]Am J Ophthalmol, 2019, 80-87.
doi: 10.1016/j.ajo.2018.09.011
[11]   徐 捷, 徐 亮. 近视防控的六维度评估及防控模式[J]. 中华眼视光学与视觉科学杂志, 2018, 20(3): 129-132
XU Jie, XU Liang. Six dimensional evaluation for myopia prevention and control[J]. Chinese Journal of Optometry Ophthalmology and Visual Science, 2018, 20(3): 129-132. (in Chinese)
[12]   董彦会, 刘慧彬, 王政和, 等. 2005—2014年中国7~18岁儿童青少年近视流行状况与变化趋势[J]. 中华预防医学杂志, 2017, 51(4): 285-289
DONG Yanhui, LIU Huibin, WANG Zhenghe, et al. The epidemic status and secular trends of myopia prevalence for Chinese children and adolescents aged 7–18 years from 2005 to 2014[J]. Chinese Journal of Preventive Medicine, 2017, 51(4): 285-289. (in Chinese)
[13]   中华人民共和国教育部. 教育部等八部门关于印发《综合防控儿童青少年近视实施方案》的通知[EB/OL]. (2018-08-30)[2020-10-20]. http://www.moe.gov.cn/srcsite/A17/moe_943/s3285/201808/t20180830_346672.html
The Ministry of Education of the People’s Republic of China. Notice of Implementation plan of comprehensive prevention and control of myopia in children and adolescents published by eight ministries including the Ministry of Education[EB/OL]. (2018-08-30)[2020-10-20]. http://www.moe.gov.cn/srcsite/A17/moe_943/s3285/201808/t20180830_346672.html. (in Chinese)
[14]   中国防盲治盲网. 2017年中国白内障复明手术报送情况排名[EB/OL]. (2018-03-28)[2020-10-18]. http://www.moheyes.com/News/Details/3bed44657e8c-40e38532-25eeb128565b
National Blindness Prevention and Treatment. The ranks of numbers of cataract surgery in China in 2017[EB/OL]. (2018-03-28)[2020-10-18]. http://www.moheyes.com/News/Details/3bed4465-7e8c-40e3-8532-25eeb128565b. (in Chinese)
[15]   MURTHYG V S, JOHNN, SHAMANNAB R, et al.Elimination of avoidable blindness due to cataract: where do we prioritize and how should we monitor this decade?[J]Ind J Ophthalmol, 2012, 60( 5): 438-455.
doi: 10.4103/0301-4738.100545
[16]   刘 平, 邹海东, 胡爱莲, 等. 白内障防盲治盲工作的关键要素[J]. 中华眼科杂志, 2017, 53(11): 801-804
LIU Ping, ZOU Haidong, HU Ailian, et al. Critical elements of cataract prevention work in China[J]. Chinese Journal of Ophthalmology, 2017, 53(11): 801-804. (in Chinese)
[17]   FLAXMANS R, BOURNER R A, RESNIKOFFS, et al.Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis[J/OL]Lancet Glob Health, 2017, 5( 12): e1221-e1234.
doi: 10.1016/S2214-109X(17)30393-5
[18]   谢立信. 对我国防盲治盲工作的几点建议[J]. 中华眼科杂志, 2017, 53(1): 1-2
XIE Lixin. Some suggestions for blindness prevention and treatment in China[J]. Chinese Journal of Ophthalmology, 2017, 53(1): 1-2. (in Chinese)
[19]   中华人民共和国人力资源社会保障部. 人力资源社会保障部关于印发国家基本医疗保险、工伤保险和生育保险药品目录(2017年版)的通知[EB/OL]. (2017-02-21)[2020-10-20]. http://www.mohrss.gov.cn/SYrlzyhshbzb/shehuibaozhang/zcwj/yiliao/201702/t20170223_266775.html
The Ministry of Human Resources and Social Security of the People’s Republic of China. Notice of Drug directory from national basic medical insurance, employment injury insurance and maternity insurance (2017) published by the Ministry of Human Resources and Social Security[EB/OL]. (2017-02-21) [2020-10-20]. http://www.mohrss.gov.cn/SYrlzyhshbzb/shehuibaozhang/zcwj/yiliao/201702/t20170223_266775.html. (in Chinese)
[20]   WANGY X, XUL, YANGH, et al.Prevalence of glaucoma in North China: the Beijing eye study[J]Am J Ophthalmol, 2010, 150( 6): 917-924.
doi: 10.1016/j.ajo.2010.06.037
[21]   HEM, FOSTERP J, GEJ, et al.Prevalence and clinical characteristics of glaucoma in adult Chinese: a population-based study in Liwan district, Guangzhou[J]Invest Ophthalmol Vis Sci, 2006, 47( 7): 2782-2788.
doi: 10.1167/iovs.06-0051
[22]   LIANGY, JIANGJ, OUW, et al.Effect of community screening on the demographic makeup and clinical severity of glaucoma patients receiving care in urban China[J]Am J Ophthalmol, 2018, 1-7.
doi: 10.1016/j.ajo.2018.07.013
[23]   梁远波, 江俊宏, 王宁利. 中国青光眼流行病学调查研究回顾[J]. 中华眼科杂志, 2019, 55(8): 634-640
LIANG Yuanbo, JIANG Junhong, WANG Ningli. Review of epidemiological studies of glaucoma in China[J]. Chinese Journal of Ophthalmology, 2019, 55(8): 634-640. (in Chinese)
[24]   中华医学会眼科学分会青光眼学组, 中国医学装备协会眼科人工智能学组. 中国基于眼底照相的人工智能青光眼辅助筛查系统规范化设计及应用指南[J]. 中华眼科杂志, 2020, 56(6): 423-432
The Subspecialty Group of Glaucoma, Chinese Ophthalmological Society, The Subspecialty Group of Ophthalmological Artificial Intelligence, China Association of Medical Equipment. Standardized design and application guideline for artificial intelligence-aided screening system for glaucoma based on fundus image in China[J]. Chinese Journal of Ophthalmology, 2020, 56(6): 423-432. (in Chinese)
[1] HU Zhenzhen,YANG Jianbin,HU Lingwei,ZHAO Yunfei,ZHANG Chao,YANG Rulai,HUANG Xinwen. Screening and clinical analysis of isovaleric acidemia newborn in Zhejiang province[J]. J Zhejiang Univ (Med Sci), 2020, 49(5): 556-564.
[2] TONG Fan,YANG Rulai,LIU Chang,WU Dingwen,ZHANG Ting,HUANG Xinwen,HONG Fang,QIAN Guling,HUANG Xiaolei,ZHOU Xuelian,SHU Qiang,ZHAO Zhengyan. Screening for hereditary tyrosinemia and genotype analysis in newborns[J]. J Zhejiang Univ (Med Sci), 2019, 48(4): 459-464.
[3] HUANG Xinwen, ZHANG Yu, HONG Fang, ZHENG Jing, YANG Jianbin, TONG Fan, MAO Huaqing, HUANG Xiaolei, ZHOU Xuelian, YANG Rulai, ZHAO Zhengyan. Screening for amino acid metabolic disorders of newborns in Zhejiang province:prevalence, outcome and follow-up[J]. J Zhejiang Univ (Med Sci), 2017, 46(3): 233-239.
[4] HONG Fang, HUANG Xinwen, ZHANG Yu, YANG Jianbin, TONG Fan, MAO Huaqing, HUANG Xiaolei, ZHOU Xuelian, YANG Rulai, ZHAO Zhengyan. Screening for newborn organic aciduria in Zhejiang province:prevalence, outcome and follow-up[J]. J Zhejiang Univ (Med Sci), 2017, 46(3): 240-247.
[5] SHEN Zhixin, GAO Enfang, WENG Wenqing, LUO Weiling. Hereditary vitreous degeneration muddy: report of ten cases[J]. J Zhejiang Univ (Med Sci), 2016, 45(6): 636-640.
[6] Yin Jinfu, Yao Ke, Jiang Jiekai, et al. CLINICAL APPLICATION OF DYC-ⅠHYPOBARIC OPERATING TABLE[J]. J Zhejiang Univ (Med Sci), 1996, 25(6): 245-248.